Identification and Study of the Action Mechanism of Small Compound That Inhibits Replication of Respiratory Syncytial Virus
-
Published:2023-08-18
Issue:16
Volume:24
Page:12933
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Shtro Anna A.1, Klabukov Artem M.1ORCID, Garshinina Anzhelika V.1, Galochkina Anastasia V.1, Nikolaeva Yulia V.1, Khomenko Tatyana M.2, Bobkov Danila E.13, Lozhkov Aleksey A.1ORCID, Sivak Konstantin V.1ORCID, Yakovlev Kirill S.1ORCID, Komissarov Andrey B.1, Borisevich Sophia S.4ORCID, Volcho Konstantin P.2ORCID, Salakhutdinov Nariman F.2
Affiliation:
1. Smorodintsev Research Institute of Influenza, Professora Popova str, 15/17, 197376 St. Petersburg, Russia 2. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Acad. Lavrentyev av. 9, 630090 Novosibirsk, Russia 3. Institute of Cytology Russian Academy of Science, Tikhoretsky av., 4, 194064 St. Petersburg, Russia 4. Ufa Chemistry Institute of the Ufa Federal Research Center, 71 Octyabrya pr., 450054 Ufa, Russia
Abstract
Respiratory syncytial virus (RSV) is known to cause annual epidemics of respiratory infections; however, the lack of specific treatment options for this disease poses a challenge. In light of this, there has been a concerted effort to identify small molecules that can effectively combat RSV. This article focuses on the mechanism of action of compound K142, which was identified as a primary screening leader in the earlier stages of the project. The research conducted demonstrates that K142 significantly reduces the intensity of virus penetration into the cells, as well as the formation of syncytia from infected cells. These findings show that the compound’s interaction with the surface proteins of RSV is a key factor in its antiviral activity. Furthermore, pharmacological modeling supports that K142 effectively interacts with the F-protein. However, in vivo studies have shown only weak antiviral activity against RSV infection, with a slight decrease in viral load observed in lung tissues. As a result, there is a need to enhance the bioavailability or antiviral properties of this compound. Based on these findings, we hypothesize that further modifications of the compound under study could potentially increase its antiviral activity.
Funder
Russian Science Foundation
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference16 articles.
1. Global Burden of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A Systematic Review and Meta-Analysis;Nair;Lancet,2010 2. Systematic Review of the Biology and Medical Management of Respiratory Syncytial Virus Infection;Black;Respir Care,2003 3. (2023, July 10). Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine. 4. (2023, July 10). Available online: https://www.fda.gov/vaccines-blood-biologics/abrysvo. 5. Khomenko, T.M., Shtro, A.A., Galochkina, A.V., Nikolaeva, Y.V., Petukhova, G.D., Borisevich, S.S., Korchagina, D.V., Volcho, K.P., and Salakhutdinov, N.F. (2021). Monoterpene-Containing Substituted Coumarins as Inhibitors of Respiratory Syncytial Virus (Rsv) Replication. Molecules, 26.
|
|